JPRN-UMIN000021758
Completed
未知
A prospective observational study about fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy - A observational study about fatigue in patients who receive nab-paclitaxel plus gemcitabine therapy
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with unresectable pancreatic cancer
- Sponsor
- Wakayama Medical University
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients with severe co\-morbidity such as heart failure, renal failure, or bowel obstruction. 2\)Patients with pregnancy. 3\)Patients with active cancer of other organs. 4\)Patients with intorerable of oral medications. 5\)Patients who is not suitable for undergoing the study safely.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
A pilot study to investigate whether fatigue is a side effect of etanercept in patients with moderate to severe psoriasispsoriasis10040785NL-OMON29881Academisch Medisch Centrum160
Not yet recruiting
Not Applicable
fatigue, and performance status in anaemic cancer patients undergoing cancer treatment.CTRI/2022/01/039371Aditi Sawant Dessai
Completed
Not Applicable
A study on the validity to the fatigue after an endurance performance for athlete by physiotherapyHealthy adultsJPRN-UMIN000024716agoya University Research Center of Health Physical Fitness and Sports15
Recruiting
Not Applicable
The effect of prediction of fatigue in formation motor training on the function of upper extremity, activity of daily living and participatioStroke.Stroke, not specified as hemorrhage or infarctionIRCT20140416017301N6Iran University of Medical Sciences60
Completed
Not Applicable
Tiredness and its causes in patients with cancers which has spreadedHealth Condition 1: null- Adult (age 18 yrs ) patients with advanced cancer receiving palliative treatment.CTRI/2018/01/011189AlIMS110